Journal
TRENDS IN IMMUNOLOGY
Volume 35, Issue 1, Pages 38-46Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.it.2013.10.007
Keywords
plasmacytoid dendritic cells; myeloid dendritic cells; cytotoxicity; TRAIL; granzyme B; antitumor therapy
Categories
Funding
- Netherlands Organization for Scientific Research (NWO ZonMW) [91776363]
- Netherlands Institute for Regenerative Medicine (NIRM) [FE50908]
- EU (ERC) [269019]
- Belgian Hematological Society
- Belgian Foundation against Cancer
- Belgian public utility foundation VOCATIO
- NWO
Ask authors/readers for more resources
Dendritic cells (DCs) are a family of professional antigen-presenting cells (APCs) that are able to initiate innate and adaptive immune responses against pathogens and tumor cells. The DC family is heterogeneous and is classically divided into two main subsets, each with its unique phenotypic and functional characteristics: myeloid DCs (mDCs) and plasmacytoid DCs (pDCs). Recent results have provided intriguing evidence that both DC subsets can also function as direct cytotoxic effector cells; in particular, against cancer cells. In this review, we delve into this understudied function of human DCs and discuss why these so-called killer DCs might become important tools in future cancer immunotherapies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
